<DOC>
	<DOCNO>NCT02222428</DOCNO>
	<brief_summary>The primary objective study compare systemic exposure BI 1744 BS CD 1857 XX ( active metabolite pro-drug BI 54903 XX ) steady state follow inhalation fix dose combination ( FDC ) 6.2 μg BI 1744 CL plus 727.3 μg BI 54903 XX ( ethanolic solution inhalation , EIS ) systemic exposure follow inhalation mono compound 10 μg BI 1744 CL ( aqueous solution inhalation , AIS ) 727.3 μg BI 54903 XX ( EIS ) , respectively , administer once-daily via Respimat® Inhaler ( Respimat® A AIS Respimat® B EIS ) 14 day healthy volunteer . Secondary objective compare exposure BI 1744 BS CD 1857 XX single dose BI 1744 CL/BI 54903 XX ( 6.2 μg/727.3 μg ) FDC mono compound , respectively ; compare exposure BI 54903 XX single dose steady state multiple dos BI 1744 CL/BI 54903 XX ( 6.2 μg/727.3 μg ) FDC mono compound , respectively ; compare safety tolerability BI 1744 CL BI 54903 XX administer BI 1744 CL/BI 54903 XX ( 6.2 μg/727.3 μg ) FDC mono compound , respectively .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Fixed Dose Combination BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus Mono Products BI 1744 CL Via Respimat® A BI 54903 XX Via Respimat® B Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Healthy male female accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( Blood pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory test Age &gt; = 21 Age &lt; = 50 year Body mass index ( BMI ) &gt; = 18.5 &lt; = 29.9 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Any finding medical examination ( include Blood pressure ( BP ) , Pulse Rate ( PR ) Electrocardiogram ( ECG ) ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 h ) within least 1 month less 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within 2 month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 40 g/day ) Drug abuse Blood donation ( 100 mL within 4 week prior administration trial ) Excessive physical activity ( within 1 week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site For female subject : Pregnancy plan become pregnant within 2 month study completion Positive pregnancy test No adequate contraception e.g. , sterilization , intrauterine device ( IUD ) , oral contraception least 3 month prior participation study Inability maintain adequate contraception whole trial period Lactation period Asthma history pulmonary hyperreactivity Hyperthyrosis Allergic rhinitis need treatment Clinically relevant cardiac arrhythmia Bacterial viral infection lung include tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>